Department of Intensive Care Medicine, Medical School, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Stem Cell Res Ther. 2022 Oct 8;13(1):496. doi: 10.1186/s13287-022-03177-4.
Microvesicles (MVs) derived from human bone marrow mesenchymal stem cell (MSC) were demonstrated to restore lung protein permeability and attenuate acute lung injury. In our previous study, we found that MSC MV increased sphingosine-1-phosphate (S1P) kinase1 mRNA levels in injured human lung microvascular endothelial cells (HLMVEC) significantly. However, the role of S1P signaling in MSC MV to restore lung protein permeability is unknown.
In this study, we hypothesized that MSC MV might restore lung permeability in part through increasing intracellular S1P signaling pathway in injured HLMVEC independent of S1P receptors. We used the transwell co-culture system to study the effect of MSC MV on protein permeability of Lipopolysaccharide (LPS) damaged HLMVEC.
Our results showed that LPS significantly increased the permeability of HLMVEC to FITC-dextran (70 kDa) within 24 h. MSC MV restores this permeability and, to a large extent, prevents the cytoskeleton protein F-actin from recombining into "actin stress fibers," and restores the positions of tight junctions and adhesion junctions in the damaged HLMVEC. This therapeutic effect of MSC MV was related to the increase in the S1P level in injured HLMVEC and was not eliminated when adding the antagonist of S1P receptor, suggesting that MSC MV to restore lung permeability was independent of S1P receptors on HLMVEC. Laser confocal further observed that Ca mobilization and Rac1 activation in LPS injured HLMVEC were increased in parallel with the increase in intracellular S1P level after MSC MV treatment.
In short, MSC MV partially restored protein permeability across HLMVEC through the intracellular S1P signaling pathway independent of S1P receptor-1.
源自人骨髓间充质干细胞(MSC)的微囊泡(MVs)被证明可恢复肺蛋白通透性并减轻急性肺损伤。在我们之前的研究中,我们发现 MSC MV 可显著增加损伤的人肺微血管内皮细胞(HLMVEC)中的鞘氨醇-1-磷酸(S1P)激酶 1 mRNA 水平。然而,S1P 信号通路在 MSC MV 恢复肺蛋白通透性中的作用尚不清楚。
在这项研究中,我们假设 MSC MV 可能通过增加损伤的 HLMVEC 中的细胞内 S1P 信号通路来部分恢复肺通透性,而不依赖于 S1P 受体。我们使用 Transwell 共培养系统研究 MSC MV 对脂多糖(LPS)损伤的 HLMVEC 蛋白通透性的影响。
我们的结果表明,LPS 在 24 小时内显著增加了 HLMVEC 对 FITC-葡聚糖(70 kDa)的通透性。MSC MV 恢复了这种通透性,并在很大程度上阻止了细胞骨架蛋白 F-肌动蛋白重新组合成“肌动蛋白应力纤维”,并恢复了损伤的 HLMVEC 中紧密连接和黏附连接的位置。MSC MV 的这种治疗作用与损伤的 HLMVEC 中 S1P 水平的增加有关,并且在添加 S1P 受体拮抗剂时并未消除,表明 MSC MV 恢复肺通透性与 HLMVEC 上的 S1P 受体无关。激光共聚焦进一步观察到,在 LPS 损伤的 HLMVEC 中,Ca 动员和 Rac1 激活与 MSC MV 处理后细胞内 S1P 水平的增加平行增加。
总之,MSC MV 通过细胞内 S1P 信号通路部分恢复了 HLMVEC 中的蛋白通透性,而不依赖于 S1P 受体-1。